TIB can recognize three tumor antigens, including MAGE-B2, in lung cancer, and the antibody titers produced against these antigens will change with the clinical course of patients, which also indicates that such antibodies can be used as tumor markers for patients.113. This evidence concerns the gene MAGEB2 and neoplasm.